Literature DB >> 12728922

Design, construction, and in vitro analyses of multivalent antibodies.

Kathy Miller1, Gloria Meng, Jun Liu, Amy Hurst, Vanessa Hsei, Wai-Lee Wong, Rene Ekert, David Lawrence, Steven Sherwood, Laura DeForge, Jacques Gaudreault, Gilbert Keller, Mark Sliwkowski, Avi Ashkenazi, Leonard Presta.   

Abstract

Some Abs are more efficacious after being cross-linked to form dimers or multimers, presumably as a result of binding to and clustering more surface target to either amplify or diversify cellular signaling. To improve the therapeutic potency of these types of Abs, we designed and generated Abs that express tandem Fab repeats with the aim of mimicking cross-linked Abs. The versatile design of the system enables the creation of a series of multivalent human IgG Ab forms including tetravalent IgG1, tetravalent F(ab')2, and linear Fab multimers with either three or four consecutively linked Fabs. The multimerized Abs target the cell surface receptors HER2, death receptor 5, and CD20, and are more efficacious than their parent mAbs in triggering antitumor cellular responses, indicating they could be useful both as reagents for study as well as novel therapeutics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12728922     DOI: 10.4049/jimmunol.170.9.4854

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.

Authors:  Qing Li; Christopher R So; Adrian Fegan; Vivian Cody; Mehmet Sarikaya; Daniel A Vallera; Carston R Wagner
Journal:  J Am Chem Soc       Date:  2010-11-15       Impact factor: 15.419

2.  Induction of apoptosis by cross-linking antibodies bound to human B-lymphoma cells: expression of Annexin V binding sites on the antibody cap.

Authors:  M Jules Mattes; Rosana B Michel; David M Goldenberg; Robert M Sharkey
Journal:  Cancer Biother Radiopharm       Date:  2009-04       Impact factor: 3.099

3.  Fab-based bispecific antibody formats with robust biophysical properties and biological activity.

Authors:  Xiufeng Wu; Arlene J Sereno; Flora Huang; Steven M Lewis; Ricky L Lieu; Caroline Weldon; Carina Torres; Cody Fine; Micheal A Batt; Jonathan R Fitchett; Andrew L Glasebrook; Brian Kuhlman; Stephen J Demarest
Journal:  MAbs       Date:  2015       Impact factor: 5.857

4.  Site-specific coupling and sterically controlled formation of multimeric antibody fab fragments with unnatural amino acids.

Authors:  Benjamin M Hutchins; Stephanie A Kazane; Karin Staflin; Jane S Forsyth; Brunhilde Felding-Habermann; Peter G Schultz; Vaughn V Smider
Journal:  J Mol Biol       Date:  2011-01-13       Impact factor: 5.469

5.  LSPR Biosensor Signal Enhancement Using Nanoparticle-Antibody Conjugates.

Authors:  W Paige Hall; Salome N Ngatia; Richard P Van Duyne
Journal:  J Phys Chem C Nanomater Interfaces       Date:  2011-02-10       Impact factor: 4.126

6.  Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation.

Authors:  Ruben J Boado; Yufeng Zhang; Yun Zhang; Chun-Fang Xia; William M Pardridge
Journal:  Bioconjug Chem       Date:  2007-02-22       Impact factor: 4.774

7.  Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system.

Authors:  Yiren Xu; John Lee; Cuong Tran; Tyler H Heibeck; Willie D Wang; Junhao Yang; Ryan L Stafford; Alexander R Steiner; Aaron K Sato; Trevor J Hallam; Gang Yin
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 8.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

9.  MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.

Authors:  Yoshimi Endo Greer; Samuel F Gilbert; Brunilde Gril; Rajesh Narwal; Danielle L Peacock Brooks; David A Tice; Patricia S Steeg; Stanley Lipkowitz
Journal:  Breast Cancer Res       Date:  2019-02-18       Impact factor: 6.466

10.  Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers.

Authors:  Edurne Rujas; Iga Kucharska; Yong Zi Tan; Samir Benlekbir; Hong Cui; Tiantian Zhao; Gregory A Wasney; Patrick Budylowski; Furkan Guvenc; Jocelyn C Newton; Taylor Sicard; Anthony Semesi; Krithika Muthuraman; Amy Nouanesengsy; Clare Burn Aschner; Katherine Prieto; Stephanie A Bueler; Sawsan Youssef; Sindy Liao-Chan; Jacob Glanville; Natasha Christie-Holmes; Samira Mubareka; Scott D Gray-Owen; John L Rubinstein; Bebhinn Treanor; Jean-Philippe Julien
Journal:  Nat Commun       Date:  2021-06-16       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.